Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upfront Obinutuzumab in Mantle Cell Lymphoma (LyMa101)
NCT02896582Phase 2Completed
- Sponsor
- LYSARC
- Start
- Nov 2016
- Primary completion
- Mar 2019
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of obinutuzumab in mantle cell lymphoma (MCL), sponsored by LYSARC. Started Nov 2016; status: completed.
02
Drugs
obinutuzumab
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on NCT02896582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02896582.